Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032095 | PMC |
| http://dx.doi.org/10.1093/brain/awu033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pomalidomide in Hereditary Hemorrhagic Telangiectasia. Reply.
N Engl J Med
December 2024
Cleveland Clinic, Cleveland, OH
Reply to Importance of Identifying Physical Manifestations That Are Associated With Hereditary Cancer Predisposition: Mutation in an African-American Patient.
JCO Oncol Pract
October 2024
William Fostier, MBBS, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom; Ari Horton, MBBS, and Ingrid Winship, PhD, MBBS, Genomic Medicine and Parkville Familial Cancer Centre, Royal Melbourne Hospital, Parkville, VIC, Australia, Department of Medicine, The University of Melbourne, Parkville, VIC, Australia; and Neil Rajan, PhD, MBBS, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.
J Natl Cancer Inst
December 2024
Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Background: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patients with early-stage HER2-negative ER-low (ER 1%-9%) BC, comparing them to ER-negative (ER <1%) and ER-intermediate (ER 10%-50%) tumors.
Methods: Among 921 patients with early-stage I-III, ER ≤50%, HER2-negative BCs, tumors were classified as ER-negative (n = 712), ER-low (n = 128), or ER-intermediate (n = 81).
Pioneering the future: CRISPR-Cas9 gene therapy for hereditary hemorrhagic telangiectasia. Author's reply.
Eur J Intern Med
September 2024
HHT Unit. Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Internal Medicine Department. Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet de Llobregat, Barcelona, Spain; Faculty of Medicine and Health Sciences. Universitat de Barcelona, Barcelona Spain. Electronic address:
Authors reply: IL-1β/DNA complex elevation distinguishes autoinflammatory disorders from autoimmune and infectious diseases.
J Intern Med
October 2024
First Department of Internal Medicine and Laboratory of Molecular Hematology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!